SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The 8-K discloses Item 5.07 results from Hooker Furnishings' Annual Meeting of Shareholders held June 9, 2026, reporting voting outcomes on three matters: election of seven directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. This is a textbook shareholder vote results disclosure with specific vote tallies for each proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from BioAge Labs' June 10, 2026 Annual Meeting of Stockholders, reporting the election of three Class II Directors (Patrick Enright, James I. Healy, and Rekha Hemrajani) and ratification of KPMG LLP as independent auditor, with detailed vote tallies for each proposal. The filing directly corresponds to Item 5.07 and is material to investors as it documents the composition of the board and auditor selection.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Warner Bros. Discovery's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of thirteen directors, ratification of PricewaterhouseCoopers LLP as auditor, a non-binding say-on-pay vote (which failed), and a sustainability ROI report proposal (which also failed). The failure of the say-on-pay vote is material to investors as it signals stockholder dissatisfaction with executive compensation.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes for three proposals: election of four directors (Wayne Burks, Jay Madhu, Peter Politis, and Anthony Saravanos), ratification of Forvis Mazars, LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals were approved by shareholders at the June 10, 2026 annual meeting.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting results for four proposals: election of three directors (Brandon M. Ribar, J. Chandler Martin, and Sam Levinson), ratification of BDO USA, P.C. as independent auditors, advisory approval of executive compensation, and approval of an amendment to the 2019 Omnibus Stock and Incentive Plan increasing authorized shares from 1,797,600 to 3,197,600. All four proposals were approved by stockholders with detailed vote tallies provided for each.
View raw filing on EDGAR →The 6-K discloses results of an Extraordinary General Meeting held on June 12, 2026, where shareholders voted on and approved two material matters: (1) a share consolidation on a 10-to-30 for 1 basis, and (2) amended and restated articles of association reflecting revised authorized share capital. The filing explicitly states "Three items of business were acted upon by the Company's shareholders at the Adjourned Annual Meeting, each of which was approved by the shareholders" and provides voting tallies (For/Against/Abstain) for each proposal. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent for a foreign private issuer.
View raw filing on EDGAR →Ponce Financial Group held its annual stockholder meeting on June 11, 2026, with shareholders voting on three proposals: election of three directors (Tsavaris, Perez, and Cintron), ratification of Forvis Mazars as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final certified results of shareholder voting at the June 9, 2026 annual meeting. The filing presents three proposals with vote tallies: election of Class III directors (company nominees prevailed over dissident nominees), ratification of Plante & Moran as independent auditor, and advisory approval of named executive officer compensation. The disclosure is material as it documents shareholder approval of key governance matters including board composition and auditor selection.
View raw filing on EDGAR →Xilio Therapeutics held its Annual Meeting of stockholders on June 10, 2026, with voting results on the election of four Class II directors (Bello, Curran, Ross, and Xu), ratification of Ernst & Young LLP as independent auditor, and approval of amendments to the 2021 Stock Incentive Plan regarding prefunded warrant shares.
View raw filing on EDGAR →This Item 5.07 disclosure presents the final voting results from Lumexa Imaging's June 10, 2026 Annual Meeting of Stockholders, including the election of three Class I directors (Lee Cooper, Brian Regan, and Caitlin Zulla) and ratification of PricewaterhouseCoopers LLP as independent auditor, with specific vote tallies for each proposal. The disclosure is a direct and complete shareholder vote results filing as contemplated by Item 5.07.
View raw filing on EDGAR →AMERISAFE held its 2026 Annual Meeting of Shareholders on June 10, 2026, with voting results reported on five matters: election of three directors, an advisory vote on executive compensation, ratification of the independent auditor, and two certificate amendments (one technical amendment approved and one officer exculpation amendment rejected).
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final results of Immunome's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting outcomes for four proposals: election of three Class III directors (Boylan, Swain, Wagenheim), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →This is a Form 8-K Item 5.07 disclosure of shareholder voting results from Janux Therapeutics' June 11, 2026 Annual Meeting of Stockholders. The filing reports final voting tallies for three proposals: election of two Class II directors (Natasha Hernday and Eric Dobmeier), ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, and the disclosure is material as it documents the outcome of the annual shareholder meeting and confirms the election of directors and auditor selection.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Vor Biopharma's Annual Meeting held on June 12, 2026. The filing reports final voting tallies for three proposals: election of two Class II directors (Andrew Levin and Fouad Namouni), approval of an amended 2021 Equity Incentive Plan, and ratification of Ernst & Young LLP as independent auditor. The detailed vote counts for each proposal are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →Marblegate Capital Corporation held its Annual Meeting of Stockholders on June 11, 2026, with 94.5% of shares represented. Stockholders voted on and approved four proposals: election of five directors, approval of the 2026 Equity Incentive Plan, ratification of Deloitte & Touche LLP as independent auditor, and approval of meeting adjournment.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Sphere Entertainment's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for four proposals: (1) election of directors to the Board (Class A and Class B stockholders voting separately), (2) ratification of the independent auditor, (3) advisory vote on named executive officer compensation, and (4) advisory vote on the frequency of executive compensation votes. The detailed vote tallies (For/Against/Withheld/Abstain/Broker Non-Votes) are the hallmark of shareholder_vote_results disclosures.
View raw filing on EDGAR →Centessa Pharmaceuticals shareholders voted on June 12, 2026 to approve the acquisition by Eli Lilly under a Scheme of Arrangement, with overwhelming support (126.7 million votes for, ~23,000 against). The Company GM also authorized implementation of the Scheme, and the AGM approved director re-elections and auditor matters.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Annexon's 2026 Annual Meeting held on June 11, 2026. The filing reports voting outcomes on four matters: election of two Class III directors (Bettina M. Cockroft and Douglas Love), ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to increase authorized common shares from 300 million to 500 million. All four proposals passed with substantial majorities, making this a material disclosure of shareholder actions.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the results of Whitehawk Therapeutics' annual meeting of stockholders held on June 11, 2026, including voting outcomes on three proposals: election of three Class III directors (Behzad Aghazadeh, Richard Maroun, and Emma Reeve), advisory approval of named executive officer compensation, and ratification of BDO USA, P.C. as independent auditor. The detailed vote tallies (For/Against/Withheld/Abstentions/Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →Definium Therapeutics held its Annual Meeting on June 11, 2026, with shareholders voting on and approving the election of seven directors, the appointment of KPMG LLP as auditor, and an amendment to the 2025 Equity Incentive Plan increasing available shares by 5,000,000.
View raw filing on EDGAR →Trinity Capital held its Annual Meeting on June 10, 2026, with stockholders voting on five proposals: director elections (Estes and Zacharia), auditor ratification (Ernst & Young LLP), say-on-pay advisory vote, frequency of future say-on-pay votes, and amendment to the Non-Employee Director Restricted Stock Plan increasing the share pool by 100,000 shares.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of TKO Group's annual meeting of stockholders held on June 10, 2026. The filing presents voting results for two proposals: election of twelve directors and ratification of KPMG LLP as independent auditor. All director nominees were elected and the auditor ratification was approved, with detailed vote tallies provided for each nominee and proposal.
View raw filing on EDGAR →Lineage Cell Therapeutics held its annual meeting of shareholders on June 10, 2026, with voting results disclosed for three matters: election of seven directors, ratification of Baker Tilly US, LLP as independent auditor, and advisory approval of named executive officer compensation. Detailed vote tallies including votes for, against, withheld, abstentions, and broker non-votes are provided for each matter.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from the June 9, 2026 annual meeting. The filing reports voting outcomes for two proposals: election of directors (Gino P. Lucadamo and Cecil D. Magpuri as Class III directors) and ratification of KPMG LLP as independent auditor, with detailed vote tallies for each. This is a material event as it reflects stockholder approval of board composition and auditor selection.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of the 2026 Annual Meeting of Shareholders held on June 10, 2026, including voting outcomes on three matters: (1) election of all nine directors with detailed vote tallies for each nominee, (2) advisory approval of named executive officer compensation with 301.7 million votes for, and (3) ratification of KPMG LLP as independent auditor. The disclosure is a textbook shareholder_vote_results event with complete voting data and outcomes.
View raw filing on EDGAR →BigBear.ai held its Annual Meeting on June 9, 2026, with shareholders voting on five proposals: election of directors Kevin McAleenan and Pamela Braden, advisory vote frequency on executive compensation (1-year approved), advisory vote on named executive officer compensation (approved), ratification of Grant Thornton LLP as auditor, and approval of a certificate amendment increasing authorized common shares from 500 million to 1 billion (approved).
View raw filing on EDGAR →This Item 5.07 discloses the results of Evercore's annual meeting of stockholders held on June 10, 2026, including final vote tabulations for four matters: (1) election of 11 directors, (2) say-on-pay advisory vote on named executive officer compensation, (3) ratification of Deloitte & Touche LLP as independent auditor, and (4) approval of the Fourth Amended and Restated 2016 Stock Incentive Plan. All four matters passed with substantial majorities. This is a routine but material disclosure of shareholder voting outcomes required by Item 5.07.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final voting results from Apogee Therapeutics' June 9, 2026 Annual Meeting of Stockholders, including three proposals: election of Class III directors (Mark C. McKenna, Jennifer Fox, and William Jones, Jr.), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies for each proposal are the core disclosure required under Item 5.07.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Vroom's Annual Meeting of Stockholders held on June 11, 2026. The filing reports voting outcomes for three proposals: election of seven directors, ratification of RSM US LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and management accountability.
View raw filing on EDGAR →The 6-K discloses the results of an extraordinary general meeting of shareholders held on June 12, 2026, with voting outcomes on nine proposals including share capital reclassification, share repurchase, share capital increase, amended articles of association, share capital reduction and reorganization, and share consolidation authority. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital restructuring and consolidation proposals are material to investors' assessment of the company's capital structure and share ownership.
View raw filing on EDGAR →This Item 5.07 discloses the final results of Senmiao Technology's Annual Meeting of Stockholders held on June 11, 2026, including voting outcomes on six proposals: director elections, auditor ratification, warrant share issuance, reverse stock split authorization, authorized share increase, and PIPE private placement approval. The detailed vote tallies for each proposal are the core disclosure, making this a textbook shareholder_vote_results event.
View raw filing on EDGAR →Athena Technology Acquisition Corp. II held an Extension Special Meeting on June 11, 2026, at which stockholders voted to amend the Certificate of Incorporation to extend the business combination deadline from June 14, 2026 to March 14, 2027, with up to nine one-month extensions permitted. The amendment passed with 9,835,330 votes in favor and zero against.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of GCM Grosvenor's 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of seven directors (Michael J. Sacks, Angela Blanton, Francesca Cornelli, David A. Helfand, Jonathan R. Levin, Stephen Malkin, and Samuel C. Scott III) and (2) ratification of Ernst & Young LLP as independent auditor. All proposals passed with substantial majorities. Shareholder vote results are material to investors as they confirm board composition and auditor appointment.
View raw filing on EDGAR →OptimizeRx held its Annual Meeting on June 9, 2026, with voting results on five proposals including director elections, say-on-pay advisory vote, two Equity Plan amendments, and auditor ratification.
View raw filing on EDGAR →The filing discloses results of a shareholder vote at an extraordinary annual meeting held on June 3, 2026, where shareholders approved an extension of the business combination deadline from June 6, 2026 to June 6, 2027. The disclosure includes specific voting outcomes (5,889,094 shares redeemed) and material financial consequences ($62.4M removed from trust account, $29M remaining), which directly affects the registrant's capital structure and timeline for completing its SPAC merger.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Live Nation's June 11, 2026 annual meeting, including election of 12 directors, an advisory vote on executive compensation, and ratification of Ernst & Young LLP as independent auditor. The filing presents detailed voting tallies for all three proposals, which is the quintessential content of Item 5.07 shareholder vote results disclosures and is material to investors assessing board composition and governance.
View raw filing on EDGAR →This Item 5.07 disclosure presents the complete results of Etsy's 2026 Annual Meeting of Stockholders held on June 9, 2026, including voting outcomes on five proposals: election of Class II directors (M. Michele Burns, Josh Silverman, and Fred Wilson), advisory approval of named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of an amendment to the 2024 Equity Incentive Plan, and rejection of a stockholder proposal on majority voting. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core disclosure required by Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from CapsoVision's 2026 Annual Meeting held on June 11, 2026. The filing reports voting outcomes for two proposals: (1) re-election of three Class I Directors (Joanne Imperial, Wen-Herng King, and Michele Harari), and (2) ratification of Baker Tilly US, LLP as independent auditor. Both proposals passed with overwhelming support. This is a routine but material Item 5.07 disclosure required by SEC rules.
View raw filing on EDGAR →Dare Bioscience held a stockholder meeting on June 11, 2026, with voting results on eight proposals including director elections, auditor ratification, say-on-pay approval, and an amendment to the 2022 Stock Incentive Plan increasing available shares by 1,500,000.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Q2 Holdings' 2026 annual meeting held on June 10, 2026. The filing reports voting outcomes on three proposals: election of seven directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, and the disclosure includes vote counts and percentages as required by Item 5.07.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Build-A-Bear Workshop's 2026 Annual Meeting held on June 11, 2026. The filing presents tabulated voting results for three proposals: election of three directors (James A Goldman, Narayan Iyengar, and Lesli Rotenberg), ratification of Ernst & Young LLP as independent accountants, and advisory approval of executive compensation. All three proposals passed by requisite majorities. This is a standard Item 5.07 disclosure of shareholder meeting outcomes, which is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the 2026 Annual General Meeting held on June 11, 2026. The filing reports the outcomes of fourteen resolutions including director elections (Resolutions 1-7), approval of the Directors' Remuneration Report (Resolution 8), say-on-pay votes (Resolutions 9-10), auditor ratification (Resolution 11), and share issuance authorizations (Resolutions 13-14), with detailed vote tallies for each resolution. This is a quintessential Item 5.07 disclosure of shareholder meeting results.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 11, 2026 Annual Meeting of Stockholders. The filing reports the vote tallies for two proposals: election of seven directors and ratification of Deloitte & Touche LLP as independent auditor. All director nominees were duly elected, and the auditor appointment was ratified. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms the composition of the board and auditor for the fiscal year.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Generac's 2026 annual meeting, covering three proposals: election of directors (Marcia J. Avedon, Bennett J. Morgan, Dominick P. Zarcone), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. The tabulated voting results with For/Against/Abstain/Broker Non-Vote columns are the hallmark of Item 5.07 disclosure and are material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of TG Therapeutics' 2026 Annual Meeting held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The disclosure is material as it documents shareholder approval of board composition and auditor ratification, though notably Proposal 3 (say-on-pay) was not approved, with 48.9 million votes against versus 31.9 million for.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the certified results of Everpure's June 10, 2026 annual meeting of stockholders. The filing presents voting outcomes for three proposals: election of three Class II directors (Andrew Brown, John Colgrove, and Roxanne Taylor), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) are the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses Item 5.07 results from Research Frontiers' Annual Meeting of Stockholders held June 11, 2026, reporting voting outcomes on four proposals: election of Darryl Daigle to the Board (6,614,329 shares in favor), ratification of CohnReznick LLP as independent accountants (19,445,284 shares in favor), non-binding approval of executive compensation (7,016,800 shares in favor), and frequency of say-on-pay votes (6,575,519 shares favoring annual frequency). This is a standard shareholder vote results disclosure material to investors' understanding of governance and compensation approval.
View raw filing on EDGAR →The filing discloses results of two stockholder votes held on June 10, 2026: (1) an annual meeting where stockholders re-elected two directors and approved executive compensation and auditor ratification, and (2) a special meeting where stockholders approved an Investment Advisory Agreement for the Company's transition from internally managed to externally managed structure. The externalization represents a material structural change to the Company's operations, making these vote results material to investors.
View raw filing on EDGAR →The exhibit announces results of an extraordinary general meeting held on June 12, 2026, where shareholders approved two key resolutions: (1) a 35-for-1 share consolidation affecting both Class A and Class B ordinary shares, and (2) amendment and adoption of new memorandum and articles of association to reflect the consolidation. This is a direct disclosure of shareholder vote results on material corporate actions, matching the shareholder_vote_results taxonomy entry.
View raw filing on EDGAR →The filing discloses results of an annual stockholder meeting held on June 9, 2026, with detailed voting outcomes on five proposals: election of five directors (Nicolas Cary, Tucker Highfield, Evan Sohn, Manuel Stotz, and Kevin Wilson), ratification of Grassi & Co. as independent auditor, advisory vote on named executive officer compensation, approval of the 2026 Equity Incentive Plan, and approval of an amendment to the 2019 Plan to increase available shares. This is a classic Item 5.07 shareholder vote results disclosure with complete voting tallies and quorum information (74.91% voting power represented).
View raw filing on EDGAR →